Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.

Authors
Category Primary study
JournalMovement disorders : official journal of the Movement Disorder Society
Year 1993
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.
Epistemonikos ID: d6c6948478b34878b9b173a6cc0d74553f96a662
First added on: May 14, 2022